The framing of 2026 as a "reset year, not a broken story" is exactly right — and the earnings breakdown makes a strong case that the market is conflating a cyclical pricing reset with a structural deterioration. The detail worth adding: the 2026 guidance of -5% to -13% growth (CER) is almost certainly sandbagging, because Novo management is recalibrating credibility after a year of disappointments and has every incentive to guide conservatively into a year they expect to recover from. The more interesting signal is in the oral Wegovy ramp — 50,000 weekly prescriptions in the first weeks of launch via largely self-pay channels suggests price elasticity is higher than the bears assumed, meaning the volume offset to US price compression may arrive faster than consensus models. The obesity market is still in the first inning of penetration; the question is never whether demand exists, but which delivery format (injectable vs. oral) captures it — and that's a transition Novo is better positioned to execute than the current valuation implies.
Very well written article. I fully share your view on strong fundamentals paired with challenges such as growth dynamics in the US and rising capital intensity. If Novo Nordisk is transitioning from a profitable compounder to a capex intense business that struggles to sustain growth, we might see the balance sheet eroding over time.
Outstanding breakdown of the Novo situation! Your framing of 2026 as a "reset year" really resonates—its a reminder that even quality compounders go through digestion periods. The contrast between volume-driven vs. price-driven growth is particulary insightful, and I think this distinction will seperate patient investors from reactionary ones. Long-term thesis intact, short-term pain absorbable.
The framing of 2026 as a "reset year, not a broken story" is exactly right — and the earnings breakdown makes a strong case that the market is conflating a cyclical pricing reset with a structural deterioration. The detail worth adding: the 2026 guidance of -5% to -13% growth (CER) is almost certainly sandbagging, because Novo management is recalibrating credibility after a year of disappointments and has every incentive to guide conservatively into a year they expect to recover from. The more interesting signal is in the oral Wegovy ramp — 50,000 weekly prescriptions in the first weeks of launch via largely self-pay channels suggests price elasticity is higher than the bears assumed, meaning the volume offset to US price compression may arrive faster than consensus models. The obesity market is still in the first inning of penetration; the question is never whether demand exists, but which delivery format (injectable vs. oral) captures it — and that's a transition Novo is better positioned to execute than the current valuation implies.
Very well written article. I fully share your view on strong fundamentals paired with challenges such as growth dynamics in the US and rising capital intensity. If Novo Nordisk is transitioning from a profitable compounder to a capex intense business that struggles to sustain growth, we might see the balance sheet eroding over time.
Can’t wait to read. One of my top three positions.
Outstanding breakdown of the Novo situation! Your framing of 2026 as a "reset year" really resonates—its a reminder that even quality compounders go through digestion periods. The contrast between volume-driven vs. price-driven growth is particulary insightful, and I think this distinction will seperate patient investors from reactionary ones. Long-term thesis intact, short-term pain absorbable.
Good one, to check in the worst case, if 3% earnings growth is assumed and not changed till
Terminal value - what is the PV?